Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: Preliminary results

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Nanni, Cristina ^a   Schiavina, Riccardo ^a   Boschi, Stefano ^a   Ambrosini, Valentina ^a   Pettinato, Cinzia ^a   Brunocilla, Eugenio ^a   Martorana, Giuseppe ^a   Fanti, Stefano ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

11C Choline; ANTI 3 18F FACBC; PET CT; Prostate cancer; PSA

Indexed keywords

ANTINEOPLASTIC AGENT; CHOLINE C 11; FLUCICLOVINE F 18; PROSTATE SPECIFIC ANTIGEN; 1 AMINO 3 FLUOROCYCLOBUTANE 1 CARBOXYLIC ACID; 1-AMINO-3-FLUOROCYCLOBUTANE-1-CARBOXYLIC ACID; CARBON; CARBOXYLIC ACID; CHOLINE; CYCLOBUTANE DERIVATIVE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE MARROW; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG UPTAKE; FALSE POSITIVE RESULT; HUMAN; KIDNEY; LIVER; MALE; MIDDLE AGED; PANCREAS; PET-CT SCANNER; PROSTATE CANCER; PROSTATECTOMY; SPLEEN; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; LIMIT OF DETECTION; METASTASIS; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; SCINTISCANNING; TUMOR RECURRENCE; DIAGNOSTIC USE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS;

AGED; CARBON RADIOISOTOPES; CARBOXYLIC ACIDS; CHOLINE; CYCLOBUTANES; HUMANS; LIMIT OF DETECTION; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84886378481     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2373-3     Document Type: Article

References (16)

1. Shoup TM, Olson J, Hoffman JM, Votaw J, Eshima D, Eshima L, et al. Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1- carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331-8.
2. Nye JA, Schuster DM, Yu W, Camp VM, Goodman MM, Votaw JR. Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18 FFACBC in humans. J Nucl Med. 2007;48(6):1017-20.
3. Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y. Transport mechanisms of trans-1-amino-3-fluoro[1- (14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol. 2012;39(1):109-19.
4. 18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011;52(5):822-9.
5. Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1- amino-3-18Ffluorocyclobutane- 1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48(1):56-63.
6. Sörensen J, Owenius R, Lax M, Johansson S. Regional distribution and kinetics of [(18)F]fluciclovine (anti-[ (18)F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(3):394-402.
7. 18F- fluorocyclobutane-1-carboxylic acid PET/CT and 111Incapromab pendetide SPECT/CT. Radiology. 2011;259:852-61.
8. Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A, et al. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184(3):938-43.
9. McConathy J, Voll RJ, YuW, Crowe RJ, Goodman MM. Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003;58 (6):657-66.
10. Pascali C, Bogni A, Itawa R, Cambiè M, Bombardieri E. [11C] Methylation on a C18 Sep-Pak cartridge: a convenient way to produce [N-methyl-11C]choline. J Labelled Comp Radiopharm. 2000;49:195-203.
11. Iatrou M, Ross SG, Manjeshwar RM, Stearns CW. A fully 3D iterative image reconstruction algorithm incorporating data corrections. Nuclear Science Symposium Conference Record, 2004, IEEE. 2004;4:2493-7.
12. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54 (5):884-90.
13. Beissert M, Lorenz R, Gerharz EW. Rational imaging in locally advanced prostate cancer. Urologe A. 2008;47(11):1405-16.
14. Reske SN, Blumstein NM, Glatting G. PET and PET/CT in relapsing prostate carcinoma. Urologe A. 2006;45(10):1240, 1242-4, 1246-8, 1250.
15. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4.
16. Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol. 2011;11:14.